Clinical trial
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
NCT00328458 · Sidney Kimmel Cancer Center at Thomas Jefferson University, Other · Completed
Key facts
| NCT number | NCT00328458 |
|---|---|
| Title | EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients |
| Official title | A Phase I, Open-label, Dose-escalation, Safety Study of the Combination of EPO906 and Radiation Therapy for the Treatment of Patients With Cancer |
| Lead sponsor | Sidney Kimmel Cancer Center at Thomas Jefferson University, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Central Nervous System Neoplasms, Head and Neck Neoplasms |
| Intervention type | Drug |
| Interventions | EPO906 (epothilone B) |
| Enrollment | 39 |
| Start date | Feb 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | Jul 1, 2009 |
| First posted | May 22, 2006 |
| Last update posted | May 2, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: